AI image analysis software for coronary plaque and FFR-CT from CCTA
Elucid builds FDA-cleared AI software that quantifies arterial plaque from coronary CT angiography. Its C++/CUDA compute layer runs on a security-hardened AWS stack (GuardDuty, Security Hub, KMS, CloudTrail), the profile of a regulated SaMD vendor. Accelerating, director-heavy hiring across engineering, product, ops and legal points to a push from clearance toward full commercial launch, with global regulatory strategy as the recurring pressure.
Notable leadership hires: Product Director
Elucid is a privately held medical technology company founded in 2013 and headquartered in Boston, Massachusetts, with 51–200 employees. It develops AI image analysis software that characterizes the type and volume of plaque in coronary arteries using CCTA scans. Its Plaque-IQ product is FDA-cleared, and the company is pursuing an FFR-CT indication derived from the same plaque algorithm to assess blockages and ischemia non-invasively. Physicians are the core users, applying the output to prioritize and personalize cardiovascular care. Hiring is concentrated in the United States.
Elucid uses C++, CUDA, Python, Go and Rust on AWS (ECS, Fargate, RDS, Redshift, EFS), with Docker, Kubernetes, Terraform, AWS CDK, GitLab, CircleCI, Datadog, New Relic, Jira and Salesforce.
Elucid is advancing global regulatory clearance for its AI medical imaging software, clinical validation of its cardiovascular imaging AI, post-market lifecycle management, and workflows for imaging analysts.
Elucid is headquartered in Boston, Massachusetts, was founded in 2013, has 51–200 employees, and currently hires in the United States.
Other companies in the same industry, closest in size
Elucid's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.